Novartis AG outlined the details of its spin-off plans for its generics and biosimilars business Sandoz on 18 August, revealing the financial terms for the big pharma’s shareholders and the date of the official separation: 4 October. Shareholders will vote on the plan at an extraordinary general meeting scheduled for 15 September.
Finance Watch: Novartis Sets October Separation Date For Sandoz Spin-Off
Generics Firm Will List On Swiss Exchange
Novartis revealed detailed terms and a 4 October spin-off date for Sandoz’s standalone debut. Also, MIRA launched a small IPO, but two firms plan to go public in SPAC mergers. Also, Mirati’s $345m offering leads follow-ons offerings and Sangon Biotech raised $290m in venture capital.
